Seres Therapeutics (MCRB) Non-Current Assets (2014 - 2026)
Seres Therapeutics (MCRB) posted Non-Current Assets of $85.8 million for Q1 2026, down 3.42% sequentially from $88.8 million in Q4 2025, and down 12.56% YoY from $98.1 million in Q1 2025.
Seres Therapeutics (MCRB) Non-Current Assets (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $85.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 12.56% year-over-year to $85.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $361.7 million (down 24.26% YoY) and the FY2025 annual result came in at $88.8 million, down 12.18% from the prior year.
- Non-Current Assets declined to $85.8 million in Q1 2026 per MCRB's latest filing, from $88.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $183.2 million in Q4 2023 and troughed at $56.6 million in Q1 2022.
- A 5-year average of $117.6 million and a median of $101.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 200.64% in 2022, then plunged 44.85% in 2025.
- Over 5 years, Non-Current Assets stood at $154.0 million in 2022, then gained by 18.94% to $183.2 million in 2023, then plunged by 44.79% to $101.1 million in 2024, then slipped by 12.18% to $88.8 million in 2025, then fell by 3.42% to $85.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $85.8 million, $88.8 million, and $91.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Seres Therapeutics | 44.36 Mn | 44.36 Mn | - | 59.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.24 Mn |
| Mar 31, 2026 | 85.78 Mn |
| Dec 31, 2025 | 88.82 Mn |
| Sep 30, 2025 | 91.95 Mn |
| Jun 30, 2025 | 95.12 Mn |
| Mar 31, 2025 | 98.10 Mn |
| Dec 31, 2024 | 101.14 Mn |
| Sep 30, 2024 | 105.81 Mn |
| Jun 30, 2024 | 172.47 Mn |
| Mar 31, 2024 | 176.08 Mn |
| Dec 31, 2023 | 183.19 Mn |
| Sep 30, 2023 | 153.31 Mn |
| Jun 30, 2023 | 155.15 Mn |
| Mar 31, 2023 | 154.11 Mn |
| Dec 31, 2022 | 154.02 Mn |
| Sep 30, 2022 | 64.36 Mn |
| Jun 30, 2022 | 63.62 Mn |
| Mar 31, 2022 | 56.64 Mn |
| Dec 31, 2021 | 51.23 Mn |
| Sep 30, 2021 | 37.48 Mn |